{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T13:15:58Z","timestamp":1773321358376,"version":"3.50.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteoarticular involvement in coccidioidomycosis is an uncommon manifestation leading to significant morbidity, but evidence surrounding it is limited. We aimed to describe the clinical characteristics of osteoarticular coccidioidomycosis and identify factors associated with treatment failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective chart review of adults age \u226518 years hospitalized with confirmed osteoarticular coccidioidomycosis at an academic tertiary care center between 2004 and 2021. We extracted demographic, clinical, microbiologic, treatment, and outcomes data. Univariable regression analysis was used to identify risk factors of disease progression or relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-two patients were reviewed, of whom 29 (91%) were male, with a median age (interquartile range [IQR]) of 46.8 (35.1\u201365.6) years and a median time of follow-up (IQR) of 84 (47\u2013127) months. The most common sites of infection were spine (n = 15, 47%) and knee (n = 9, 28%). Itraconazole was the most common antifungal used (n = 16, 50%), followed by posaconazole (n = 8, 25%), and surgery was performed in 24 (75%) patients. The median treatment duration (IQR) was 45.0 (13.3\u201366.7) months, with 26 (81%) patients remaining on antifungals through the last day of follow-up. Fifteen (47%) patients experienced progression and\/or relapse. Knee (odds ratio [OR], 18.29; 95% CI, 91\u2013175.35) and multisite infections (OR, 6.56; 95% CI, 1.10\u201339.32) were associated with disease progression and\/or relapse, while spine infection was associated with lower rates of progression and\/or relapse (OR, 0.20; 95% CI, 0.44\u20130.90).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with osteoarticular coccidioidomycosis required prolonged therapy with a substantial risk of disease progression or relapse. Knee and multisite infections were associated with poorer outcomes. Larger studies are needed to validate these findings and optimize treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag103","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T12:30:33Z","timestamp":1771763433000},"source":"Crossref","is-referenced-by-count":0,"title":["Osteoarticular Coccidioidomycosis in California: A Single-Center Experience"],"prefix":"10.1093","volume":"13","author":[{"given":"Radhika","family":"Arya","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine , Stanford, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Dzinoreva","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford University , Stanford, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3545-7743","authenticated-orcid":false,"given":"Traci","family":"Shiu","sequence":"additional","affiliation":[{"name":"Stritch School of Medicine, Loyola University Chicago , Maywood, Illinois ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0896-3760","authenticated-orcid":false,"given":"Elizabeth","family":"Thottacherry","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine , Stanford, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1194-8222","authenticated-orcid":false,"given":"Amy","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine , Stanford, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-2785","authenticated-orcid":false,"given":"Jenny","family":"Aronson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine , Stanford, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanthi","family":"Kappagoda","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine , Stanford, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-1663","authenticated-orcid":false,"given":"Daisuke","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine , Stanford, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"2026031116101569500_ofag103-B1","author":"Centers for Disease Control and Prevention"},{"key":"2026031116101569500_ofag103-B2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/jof9101002","article-title":"Coccidioidomycosis osteoarticular dissemination","volume":"9","author":"Moni","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"2026031116101569500_ofag103-B3","doi-asserted-by":"crossref","first-page":"e00086-19","DOI":"10.1128\/cmr.00086-19","article-title":"Osteoarticular mycoses","volume":"35","author":"Gamaletsou","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"2026031116101569500_ofag103-B4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1196\/annals.1406.000","article-title":"State-of-the-art treatment of coccidioidomycosis skeletal infections","volume":"1111","author":"Blair","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"2026031116101569500_ofag103-B5","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1093\/cid\/ciw360","article-title":"2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis","volume":"63","author":"Galgiani","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026031116101569500_ofag103-B6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.amjmed.2011.10.018","article-title":"Vertebral coccidioidomycosis: presentation and multidisciplinary management","volume":"125","author":"Szeyko","year":"2012","journal-title":"Am J Med"},{"key":"2026031116101569500_ofag103-B7","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s10096-014-2149-0","article-title":"Dimorphic fungal osteoarticular infections","volume":"33","author":"Rammaert","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026031116101569500_ofag103-B8","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/diagnostics12030714","article-title":"Skeletal infections caused by Coccidioides species","volume":"12","author":"Koutserimpas","year":"2022","journal-title":"Diagnostics"},{"key":"2026031116101569500_ofag103-B9","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/jof10040270","article-title":"Diagnosis, treatment, and outcome of coccidioidal osseous infections: a systematic review","volume":"10","author":"Tsantes","year":"2024","journal-title":"J Fungi (Basel)"},{"key":"2026031116101569500_ofag103-B10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5194\/jbji-9-197-2024","article-title":"Musculoskeletal manifestations of lower-extremity coccidioidomycosis: a case series","volume":"9","author":"Estes","year":"2024","journal-title":"J Bone Jt Infect"},{"key":"2026031116101569500_ofag103-B11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.idc.2024.11.012","article-title":"Coccidioidomycosis","volume":"39","author":"Donovan","year":"2025","journal-title":"Infect Dis Clin North Am"},{"key":"2026031116101569500_ofag103-B12","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-133-9-200011070-00009","article-title":"Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group","volume":"133","author":"Galgiani","year":"2000","journal-title":"Ann Intern Med"},{"key":"2026031116101569500_ofag103-B13","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"},{"key":"2026031116101569500_ofag103-B14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/INF.0000000000003540","article-title":"Pediatric musculoskeletal coccidioidomycosis in central California: a single center experience","volume":"41","author":"Naeem","year":"2022","journal-title":"Pediatr Infect Dis J"},{"key":"2026031116101569500_ofag103-B15","doi-asserted-by":"crossref","first-page":"e01318-18","DOI":"10.1128\/JCM.01318-18","article-title":"Coccidioidomycosis complement fixation titer trends in the age of antifungals","volume":"56","author":"McHardy","year":"2018","journal-title":"J Clin Microbiol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag103\/67093031\/ofag103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag103\/67093031\/ofag103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/3\/ofag103\/67093031\/ofag103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:10:25Z","timestamp":1773259825000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag103\/8496235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag103","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,24]]},"article-number":"ofag103"}}